Hull University Hospital opens state-of-the-art eye surgery suite

The Bausch + Lomb refractive laser eye surgery suite represents a “first for the NHS,” hospital leaders suggest

Hull university hospital
Hull University Hospital has opened a new state-of-the-art eye surgery suite, which it suggests will help to improve the accuracy of complex surgeries as well as support new research into challenging eye conditions.

The new Allam Refractive Laser Suite will help to treat NHS patients across the North of England undergoing cataract procedures and corneal surgery.

The opening marks the launch of Bausch + Lomb’s first fully-integrated refractive laser eye surgery suite.

A key feature of the new suite is the Victus Femtosecond Laser, which supports eye surgeons in precision and control for cataract and corneal surgical procedures, as well as the Teneo 317 M2 – which Bausch + Lomb suggests is the fastest laser of its kind.

Reflecting on the benefits of the new suite, Colin Vize, consultant eye surgeon and medical director at Hull University Hospital (pictured), said: “Up to this point, we have relied on highly-skilled surgeons to perform corneal transplants with steady hands and a keen eye. Current manual dissection techniques literally require a surgeon that can estimate a dissection plane to the level of microns. That’s sometimes even smaller than a grain of sand – all without assistance.”

Mr Vize added that, with the technology in the new suite, the procedures can be performed with “greater precision and control.”

“This means that patients can benefit from even more reliable and improved outcomes, so they can enjoy their sight again and embrace life to the full,” he added.

Thanking local businessman and philanthropist, Dr Assem Allam, who funded the new suite, Chris Long, chief executive of Hull University Teaching Hospitals NHS Trust, said of the launch: “This state-of-the-art technology, brought together in one service, represents a true national ‘first’ for the NHS.”

Any income generated from the procedures will be re-invested back into new research and technology, Mr Long added, “So we can continually enhance our services for patients.”